A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M.
de Vries M, et al. Among authors: loose p.
J Virol. 2021 Mar 10;95(7):e01819-20. doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23.
J Virol. 2021.
PMID: 33622961
Free PMC article.